These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32887021)

  • 1. Serum proteomics analysis of candidate predictive biomarker panel for the diagnosis of trastuzumab-based therapy resistant breast cancer.
    Yang T; Fu Z; Zhang Y; Wang M; Mao C; Ge W
    Biomed Pharmacother; 2020 Sep; 129():110465. PubMed ID: 32887021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating metabolites serve as diagnostic biomarkers for HER2-positive breast cancer and have predictive value for trastuzumab therapy outcomes.
    Mao C; Wang M; Li L; Tang JH
    J Clin Lab Anal; 2022 Feb; 36(2):e24212. PubMed ID: 34994982
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Insights into the Development of Preclinical Trastuzumab- Resistant HER2+ Breast Cancer Models.
    Gonzalez-Alonso P; Cristobal I; Zazo S; Martin-Aparicio E; Chamizo C; Madoz-Gurpide J; Rovira A; Eroles P; Lluch A; Albanell J; Rojo F
    Curr Med Chem; 2018; 25(17):1976-1998. PubMed ID: 27993109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
    Li H; Liu J; Chen J; Wang H; Yang L; Chen F; Fan S; Wang J; Shao B; Yin D; Zeng M; Li M; Li J; Su F; Liu Q; Yao H; Su S; Song E
    Nat Commun; 2018 Apr; 9(1):1614. PubMed ID: 29691399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transcriptome-wide identification of mRNAs and lincRNAs associated with trastuzumab-resistance in HER2-positive breast cancer.
    Merry CR; McMahon S; Forrest ME; Bartels CF; Saiakhova A; Bartel CA; Scacheri PC; Thompson CL; Jackson MW; Harris LN; Khalil AM
    Oncotarget; 2016 Aug; 7(33):53230-53244. PubMed ID: 27449296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MiR-200c/FOXP3 Network: A Promising Biomarker for Predicting Trastuzumab Response in HER2-Positive Breast Cancer.
    Othman MS; Elabbasy MT; Aref AM; Altaleb AA; Mohammed MH; Soliman DAM; El-Khazragy N
    Technol Cancer Res Treat; 2024; 23():15330338241292226. PubMed ID: 39429192
    [No Abstract]   [Full Text] [Related]  

  • 7. Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer.
    Horii R; Nitta H; Nojima M; Maruyama R; Ueno T; Ito Y; Ohno S; Banks P; Kanda H; Akiyama F
    Virchows Arch; 2021 Jul; 479(1):13-21. PubMed ID: 33496805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CTMP, a predictive biomarker for trastuzumab resistance in HER2-enriched breast cancer patient.
    Chen YC; Li HY; Liang JL; Ger LP; Chang HT; Hsiao M; Calkins MJ; Cheng HC; Chuang JH; Lu PJ
    Oncotarget; 2017 May; 8(18):29699-29710. PubMed ID: 27447863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
    Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UGT1A7 altered HER2-positive breast cancer response to trastuzumab by affecting epithelial-to-mesenchymal transition: A potential biomarker to identify patients resistant to trastuzumab treatment.
    Wang C; Bai C; Zhang Z; Zhou H; Gao H; Wang S; Yuan Y
    Cancer Gene Ther; 2024 Oct; 31(10):1525-1535. PubMed ID: 39122832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
    Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
    Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring treatment efficacy and resistance in breast cancer patients via circulating tumor DNA genomic profiling.
    Chen Z; Sun T; Yang Z; Zheng Y; Yu R; Wu X; Yan J; Shao YW; Shao X; Cao W; Wang X
    Mol Genet Genomic Med; 2020 Feb; 8(2):e1079. PubMed ID: 31867841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer.
    Dong H; Wang W; Chen R; Zhang Y; Zou K; Ye M; He X; Zhang F; Han J
    Int J Oncol; 2018 Sep; 53(3):1013-1026. PubMed ID: 30015837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. POU4F1 confers trastuzumab resistance in HER2-positive breast cancer through regulating ERK1/2 signaling pathway.
    Wu D; Jia HY; Wei N; Li SJ
    Biochem Biophys Res Commun; 2020 Dec; 533(3):533-539. PubMed ID: 32988584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer.
    Sun C; Yang F; Zhang Y; Chu J; Wang J; Wang Y; Zhang Y; Li J; Li Y; Fan R; Li W; Huang X; Wu H; Fu Z; Jiang Z; Yin Y
    Cell Physiol Biochem; 2018; 49(2):419-431. PubMed ID: 30153663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer.
    Palomeras S; Diaz-Lagares Á; Viñas G; Setien F; Ferreira HJ; Oliveras G; Crujeiras AB; Hernández A; Lum DH; Welm AL; Esteller M; Puig T
    Breast Cancer Res; 2019 Jul; 21(1):79. PubMed ID: 31277676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interaction between carcinoembryonic antigen-related cell adhesion molecule 6 and human epidermal growth factor receptor 2 is associated with therapeutic efficacy of trastuzumab in breast cancer.
    Iwabuchi E; Miki Y; Kanai A; Miyashita M; Kijima G; Hirakawa H; Suzuki T; Ishida T; Sasano H
    J Pathol; 2018 Nov; 246(3):379-389. PubMed ID: 30058236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined transcriptome and proteome analysis reveals MSN and ARFIP2 as biomarkers for trastuzumab resistance of breast cancer.
    Shi X; Sheng Y; Fei H; Wei B; Zhang Z; Xia X; Mao C; Si X
    Breast Cancer Res Treat; 2024 Aug; 207(1):187-201. PubMed ID: 38750271
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of KLK10 as a therapeutic target to reverse trastuzumab resistance in breast cancer.
    Wang Z; Ruan B; Jin Y; Zhang Y; Li J; Zhu L; Xu W; Feng L; Jin H; Wang X
    Oncotarget; 2016 Nov; 7(48):79494-79502. PubMed ID: 27825132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
    Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
    Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.